Oct 8, 2026 · 54 min
Personalized medicine challenges one-size-fits-all HRT
206. Dr. Pamela Smith: The Truth About Hormone Replacement Therapy—HRT, Menopause & Cancer Risk
Hormone therapy can affect cancer risk, metabolism, bone health, and quality of life, making individualized testing and risk assessment consequential.
- 1Hormone replacement decisions should account for symptoms, genetics, metabolites, and an individual baseline rather than standardized protocols.
- 2Estrogen metabolism, gut health, toxins, blood sugar, and methylation form interconnected pathways in breast-cancer risk discussions.
- 3Fasting insulin, cortisol patterns, nutrient status, and bone health can reveal risks before conventional disease thresholds are crossed.
Don't miss
Smith reframes hormone therapy as one part of a wider risk assessment involving estrogen metabolites, genetics, gut health, toxins, and metabolic markers.
The brief
Pamela W. Smith traces her move from emergency medicine into personalized hormone care, prompted in part by insomnia that led her to investigate progesterone and root causes.
The conversation revisits the Women’s Health Initiative and argues that standardized hormone prescriptions obscured how estrogen, progesterone, testosterone, and related hormones function in balance.
Smith links estrogen metabolites to genetics and methylation, while warning that testing and methylated vitamins should reflect individual biology rather than blanket assumptions.
The discussion widens from hormones to gut health, toxins, insulin, cortisol, exercise, and bone health, treating these systems as connected inputs to disease risk.
The standout idea is prevention before diagnosis: fasting insulin, glucose monitoring, cortisol patterns, nutrient testing, and genetic information may guide earlier, more tailored decisions.
Books & mentions
Some links are affiliate links — PodLume may earn a commission if you buy.
